EOErika Ogawa

Erika Ogawa

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Erika Ogawa has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Storage‐Associated Reduction in ELISA‐Detectable Walnut Allergen Levels Does Not Reflect Functional Allergenicity

    by Sayaka Hamaguchi, Tomoki Yaguchi, Daisuke Harama, Kotaro Umezawa, Kenji Toyokuni, Erika Ogawa, Yasuhito Yamamoto, Hideaki Morita, Tatsuki Fukuie, Yukihiro Ohya, et al.

    Summary: Commercial ELISA measurements declined during walnut powder storage, while total protein concentrations remained broadly stable. Patient serum IgE binding and basophil activation showed no consistent decline corresponding to ELISA measurements.

  • Open Access

    First Japanese case of DNAJC12 deficiency diagnosed after 18 years of follow‐up for mild hyperphenylalaninemia

    by Erika Ogawa, Chika Takano, Natsuko Arai‐Ichinoi, Takashi Hamazaki, Hideo Sasai, Ichiro Morioka, Mika Ishige

  • Open Access

    小児ミトコンドリア病の診断スキームと新規遺伝子を含む最近の知見

    by Erika Ogawa

    The main function of mitochondria is to produce energy, and the respiratory chain complex embedded in theinner membrane of mitochondria is the site of energy production. Its disorder leads to dysfunction in variousorgans, a condition called mitochondrial respiratory chain complex deficiency (MRCD), or simply, mitochondrialdisease. Over 1,500 proteins are involved in respiratory chain reactions, and only 13 of them are encoded bymitochondrial DNA (mtDNA). The rest are coded by nuclear genes. Currently, there are more than 420 genes recognized to cause MRCD, and many of them are nuclear. MRCD caused by mtDNA mutations is maternally inherited, while that caused by nuclear genes is inherited in an autosomal recessive, autosomal dominant, or X-linkedmanner. Over 3,000 cases of pediatric MRCD have been analyzed in Japan since 2007, and over 480 cases havebeen genetically diagnosed. The most frequent genetic causes of MRCD in Japan are MT-TL1, MT-ATP6, PDHA1,ECHS1, and MT-ND6. Cases with younger onset are more likely to be caused by mutations in nuclear genes.Recently, novel nuclear genes such as GTPBP3, IARS and ATAD3 have been reported to cause MRCD. We arenow aware that MRCD may be the cause of many diseases in children, including cardiomyopathies, neonatal fatalhyperlactatemia, and hepatopathies. Neonatal-onset mitochondrial disease is defined as any MRCD with onsetin the neonatal period. Since initial symptoms often appear within the first two days of life, MRCD should besuspected in any neonates not doing well in this period. Mitochondrial nephropathy is also gaining attention, andit can be suspected by a characteristic pathological finding called granular swollen epithelial cells. Large-scaleepidemiologic studies have revealed outcomes and risk factors for mitochondrial cardiomyopathies, neonatalonset mitochondrial disease, and Leigh disease. With genetic analysis of MRCD now covered by public healthinsurance, research is expected to accelerate even more in the near future.

  • Open Access

    Mortality of Japanese patients with Leigh syndrome: Effects of age at onset and genetic diagnosis

    by Erika Ogawa, Takuya Fushimi, Minako Ogawa‐Tominaga, Masaru Shimura, Makiko Tajika, Keiko Ichimoto, Ayako Matsunaga, Tomoko Tsuruoka, Mika Ishige, Tatsuo Fuchigami, et al.

    Leigh syndrome is a major phenotype of mitochondrial diseases in children. With new therapeutic options being proposed, assessing the mortality and clinical condition of Leigh syndrome patients is crucial for evaluating therapeutics. As data are scarce in Japan, we analysed the mortality rate and clinical condition of Japanese Leigh syndrome patients that we diagnosed since 2007. Data from 166 Japanese patients diagnosed with Leigh syndrome from 2007 to 2017 were reviewed. Patients' present status, method of ventilation and feeding, and degree of disability as of April 2018 was analysed. Overall, 124 (74.7%) were living, 40 (24.1%) were deceased, and 2 (1.2%) were lost to follow‐up. Median age of living patients was 8 years (1‐39 years). Median length of disease course was 91 months for living patients and 23.5 months for deceased patients. Nearly 90% of deaths occurred by age 6. Mortality rate of patients with onset before 6 months of age was significantly higher than that of onset after 6 months. All patients with neonatal onset were either deceased or bedridden. MT‐ATP6 deficiency caused by m.8993T>G mutation and MT‐ND5 deficiency induced a severe form of Leigh syndrome. Patients with NDUFAF6, ECHS1, and SURF1 deficiency had relatively mild symptoms and better survival. The impact of onset age on prognosis varied across the genetic diagnoses. The clinical condition of many patients was poor; however, few did not require mechanical ventilation or tube‐feeding and were not physically dependent. Early disease onset and genetic diagnosis may have prognostic value.